Trusted Press Release Distribution   Plans | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
Fact.mr
www.factmr.com/
James Jones
info@factmr.com
35316111593
Suite 9884 27 Upper Pembroke Street, Dublin 2


Bookmark and Share
Ovarian Cancer Diagnostics Market: Epithelial Tumours Segment larger than the other two Combined
The Fact.MR report on global ovarian cancer diagnostics market projects that by the end of 2017, around US$ 638 Mn worth of revenues will be procured globally through diagnosis of ovarian cancer

BriefingWire.com, 4/17/2019 - The Fact.MR report on global ovarian cancer diagnostics market projects that by the end of 2017, around US$ 638 Mn worth of revenues will be procured globally through diagnosis of ovarian cancer. Emergence of multi-purpose diagnosis tests on ovarian cancer is expected to boost the market’s expansion in the future. Towards the end of 2022, the global market for ovarian cancer diagnostics is anticipated to expand at 8.7% CAGR, bringing in revenues worth a little over US$ 966 Mn.

Request Sample Report:

www.factmr.com/connectus/sample?flag=S&rep_id=51

Epithelial Tumours Segment larger than the other two combined

The Epithelial Tumours Segment is anticipated to grow to almost US $ 880 million by the end of the forecast period and it already accounts for an 11% revenue share in 2017 itself.  North America alone represents almost 2/5th of the market and it should touch US$ 330 million by the end of 2022. The germ cell carcinoma tumours segment is much smaller by comparison and is only poised to be a US$ 50 million market by the end of the five year study.

Focus on CA 125 test segment in the ovarian cancer diagnostics market

The CA 125 test segment could be worth roughly US$ 440 million in 2022 and some key stakeholders may decide to focus on this lucrative test over all other available alternatives in the ovarian cancer diagnostics market. However, the HER 2 segment also accounts for a 3.1% revenue share in 2017 and it would be unwise to do so. On the other hand, the BRCA segment in North America alone could grow with a CAGR of 8.3% for the period 2017-2022, making it imperative for companies to hedge their bets in the ovarian cancer diagnostics market.

Browse Full Report with TOC-

www.factmr.com/report/51/ovarian-cancer-diagnostics-market

Europe’s ovarian cancer diagnostics market is expected to showcase a relatively faster growth in terms of revenues. Robust healthcare infrastructure in a majority of European countries is observed to boost the adoption of ovarian cancer diagnostics in this region. Towards the end of 2022, Europe will record revenues worth a little over US$ 315 Mn in its ovarian cancer diagnostics market.

The report on the global market for ovarian cancer discusses such key factors that govern the economics of ovarian cancer diagnostics across the globe. Some of the key influences for the growth of global ovarian cancer diagnostics market include:

Rising presence of carcinogenic elements in common consumables

Surging exposure to toxic substances in factories & industrial settings

Lack of awareness related to causes, symptoms, and preventive measures for ovarian cancer

High healthcare costs, deterring ovarian cancer patients from seeking optimum diagnosis

With growing incidence of ovarian cancer, the future generations will witness a more accessible, affordable, and diagnosis-associated treatment for ovarian cancer. As ovarian cancer research organizations & societies struggle to develop effective medications in tight-budgeted capitals, governments are deploying initiatives that boost the awareness of ovarian cancer.

The report has also profiled leading players in the global market for ovarian cancer diagnostics, which include Quest Diagnostics Incorporated, Myriad Genetics Inc., AstraZeneca plc., Epigenomics AG, Illumina, Inc., Bio-Rad Laboratories, Inc., Siemens AG, Thermo Fisher Scientific Inc., Roche Holding AG., and Abbott Laboratories.

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2019 Proserve Technology, Inc.